Donor cells join fight against nasopharyngeal cancer recurrence
NCT ID NCT07247201
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This early-phase trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can lower the chance of cancer returning in 31 people with advanced nasopharyngeal cancer. The study first finds the safest dose of NK cells, then checks if the combination reduces a key cancer marker (EBV-DNA) in the blood. Participants will be closely monitored for side effects and recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Singapore General Hospital
Singapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.